Table 6.
Applications of nanoparticle in N2B delivery for treatment of depression.
| Drug | Nanocarrier | Lipids | Surfactant/Co-Surfactant | Surface Modification | Size, nm |
Z-Potential, mV |
PDI | EE, % |
DTE, % |
DTP, % |
Ref. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Venlafaxine | Chitosan Nanoparticle | - | - | - | 167 ± 6.5 | +23.83± 1.76 | 0.367 ± 0.045 | 79.3 ± 2.6 | 508.59 | 80.34 | [256] |
| Alginate Nanoparticle | - | - | - | 173.7 ± 2.5 | +37.40 ± 1.74 | 0.391 ± 0.045 | 81.3 ± 1.9 | 425.77 | 76.52 | [134] | |
| Desvenlafaxine | PLGA Nanoparticle | - | - | Chitosan | 172.5 ± 10.2 | +35.63 ± 8.25 | 0.254 ± 0.02 | 76.4 ± 4.2 | 544.23 | 81.62 | [257] |
| Buspirone | TC Nanoparticle | - | - | - | 226.7 ± 2.52 | - | 0.483 ± 0.031 | 81.13 ± 2.8 | 78.94 ± 15.31 | 95.97 ± 11.31 | [258] |
| Agomelatine | SLN | Gelucire 43/01 | PVA/SDC | - | 167.70 ± 0.42 | −17.90 ± 2.70 | 0.12 ± 0.1 | 91.25 ± 1.7 | 190.02 | 47.37 | [259] |
| Selegiline | TC Nanoparticle | - | - | - | 215 ± 34.71 | +17.06 | 0.214 ± 0.0421 | 70 ± 2.71 | - | - | [131] |
Abbreviations: PDI: polydispersity index; EE: Encapsulation efficiency; DTE: Drug targeting efficiency; DTP: Direct transport percentage; PEG: polyethylene glycol; PLGA: poly lactic-co-glycolic acid; PVA: polyvinyl alcohol; SDC: sodium deoxycholate; SLN: solid lipid nanoparticle; TC: thiolated-chitosan.